Enrollment Completed In Phase III Studies Of Nexavar For Patients With Metastatic Melanoma And Liver Cancer

... Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals,Inc. (Nasdaq: ONXX) today announced the completion of patient enrollment intwo randomized, double-blind, Phase III clinical trials; one administeringNexavar(R) (sorafenib) tablets in combination with the chemotherapeuticagents carboplatin and paclitaxel in patients with advanced metastaticmelanoma and another administering Nexavar as a single agent in patientswith advanced hepatocellular carcinoma (HCC), or liver cancer... click link for more info. ...